CJC-1295 vs Sermorelin
A side-by-side research comparison of CJC-1295 and Sermorelin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | CJC-1295 | Sermorelin |
|---|---|---|
| Full name | CJC-1295 (Modified GRF 1-29) | Sermorelin Acetate (GHRH 1-29) |
| Category | Growth Hormone | Growth Hormone |
| Status | Research compound | Previously FDA-approved (discontinued 2008) |
| Mechanism | Binds GHRH receptors on anterior pituitary somatotrophs, stimulating cAMP-dependent GH synthesis and pulsatile release. | Binds GHRH receptors on anterior pituitary via cAMP-PKA pathway. Preserves natural feedback regulation and pulsatility unlike exogenous HGH. |
| Molecular weight | 3,368 Da (without DAC) | 3,358 Da |
| Half-life | 30 minutes (no DAC) / 8 days (with DAC) | 10-20 minutes |
| Bioavailability | High (SubQ) | Moderate (SubQ) |
| Typical dose | 100-300 mcg | 200-300 mcg |
| Frequency | 1-3x daily (no-DAC) | Once daily before bed |
| Route | Subcutaneous injection | Subcutaneous injection |
CJC-1295 reported benefits
- Increased GH production
- Improved body composition
- Enhanced recovery
- Better sleep quality
- Anti-aging effects
- Fat loss
Sermorelin reported benefits
- Natural GH pulsatility preserved
- Improved sleep quality
- Body composition improvement
- Skin elasticity
- Long safety record
Related comparisons
Research and educational reference only. Not medical advice.